The Purpose of This Study is to Compare the Therapy Effects and Clinical Safety of a Stomach Ulcers Drug, Polaprezinc (POL) With a Marketed AR-inhibitors, Abiraterone, Enzalutamide, or Darolutamimde in Chinese Patients With Castration-resistant Prostate Cancer (CRPC).
Latest Information Update: 13 Jul 2023
At a glance
- Drugs Polaprezinc (Primary)
- Indications Prostate cancer
- Focus Pharmacodynamics
- Acronyms POL-CRPC
Most Recent Events
- 27 Sep 2022 New trial record